Journal Watch · The Lancet Oncology · 2026

Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.

HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

Tannock IF, Brundage M, Booth CM et al.The Lancet Oncology3 min readPharma relevance 75/100

DOI: 10.1016/s1470-2045(26)00333-5PMID: 42810369Study type: randomised / controlled clinical trial

TL;DR

HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

Key findings

  • Once the proportion of patients with specific adverse changes in symptoms is identified, it is possible to determine if specific patient group(s) are at particular risk for these effects.
  • HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

What they did

To facilitate understanding by oncologists and patients, we recommend reporting in publications the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration in a relevant and validated HRQOL scale, and the duration of this deterioration during and after treatment completion, with appropriate handling of missing data and intercurrent events. HRQOL assessment should include symptoms, functioning domains, and overall HRQOL. Between-group comparisons should address key HRQOL outcomes (as defined by both oncologists and patients) supplemented by descriptive outcomes across remaining HRQOL domains.

Full abstract (original)

Background: The goal of adjuvant systemic therapy after locoregional treatment of cancer is to increase the probability of cure by eradicating micro-metastases. Adjuvant treatment adds side-effects and can impair health-related quality of life (HRQOL); this must be balanced against a reduction in the probability of recurrence, which has a substantial negative effect on HRQOL. Since many adjuvant therapies lead to small gains in relapse-free or overall survival, the severity and duration of treatment-related side-effects and their impact on patient functioning and overall HRQOL are relevant to clinical decision making.

What they did: To facilitate understanding by oncologists and patients, we recommend reporting in publications the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration in a relevant and validated HRQOL scale, and the duration of this deterioration during and after treatment completion, with appropriate handling of missing data and intercurrent events. HRQOL assessment should include symptoms, functioning domains, and overall HRQOL. Between-group comparisons should address key HRQOL outcomes (as defined by both oncologists and patients) supplemented by descriptive outcomes across remaining HRQOL domains.

Results & conclusions: Once the proportion of patients with specific adverse changes in symptoms is identified, it is possible to determine if specific patient group(s) are at particular risk for these effects. HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

Abstract © the authors / The Lancet Oncology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/s1470-2045(26)00333-5 · PubMed 42810369.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking The Lancet Oncology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this The Lancet Oncology study find?

HRQOL information should be included in the primary report of trials evaluating adjuvant therapy as it is key to informed decisions about treatment choice, and updated long-term evaluation is also important to capture any lasting deficits in HRQOL.

What type of study is this?

It is a randomised / controlled clinical trial, published in The Lancet Oncology in 2026. To facilitate understanding by oncologists and patients, we recommend reporting in publications the proportion of patients receiving adjuvant therapy who experience a prespecified deterioration in a relevant and validated HRQOL scale, and the duration of this deterioration during and after treatment completion, with appropriate handling of missing data and intercurrent events.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/s1470-2045(26)00333-5. PubMed ID: 42810369. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Tannock IF, Brundage M, Booth CM et al.. Reporting health-related quality of life in randomised clinical trials evaluating adjuvant systemic therapy: recommendations of Common-Sense Oncology and the European Organisation for Research and Treatment of Cancer.. The Lancet Oncology (2026). DOI: 10.1016/s1470-2045(26)00333-5.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/reporting-health-related-quality-of-life-in-randomised-clinical-trials-e-003335/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides